Kevin Trapp joined DBV in August 2018 and serves as Chief Commercial Officer responsible for all Commercial Operations globally. He is a member of the Executive Committee. Prior to joining DBV, Mr. Trapp served in a variety of leadership positions during a more than 25-year career at Bristol-Myers Squibb in the areas of finance, sales, marketing and general management. His last position was Senior Vice President, Portfolio & Access Strategy. Over the course of his career, Mr. Trapp has been responsible for a $4 billion U.S. portfolio in the areas of immunology, neuroscience and virology. He was directly involved in the launching over 10 products and indications on leading brands such as Abilify®, Atripla®, Reyataz® and Daklinza®. He earned a bachelor’s degree from the University of Connecticut School of Business and completed the General Management Program from CEDEP at INSEAD, Fountainebleu, France.